We have advised Infinitopes, an Oxford-based clinical-stage cancer vaccine biotechnology company, on its additional US$15.4 million seed financing.
The latest investment which brings the total seed financing to US$35 million was co-led by Octopus Ventures and new investor Amplify Bio, with further participation from new investor Macmillan Cancer Support alongside existing investors Cancer Research Horizons and Manta Ray Ventures. The funding will support the launch of Infinitopes' first-in-human clinical trial of ITOP1, its precision therapeutic vaccine aimed at preventing recurrence in oesophageal cancer.
Commenting on the transaction, corporate partner Ross McNaughton said: "We are delighted to support Infinitopes at this pivotal stage in their development. The cancer vaccine sector represents one of the most dynamic and impactful frontiers in modern medicine, and Infinitopes’ AI-driven approach to precision immunotherapy holds significant promise for transforming patient outcomes in areas of high unmet clinical need. We are excited to be part of this journey and look forward to their continued progress as they advance through clinical trials and beyond."
Jonathan Kwok, Chief Executive Officer of Infinitopes, added: “This new funding unlocks our potentially groundbreaking Phase I/IIa trial, enabling proof-of-concept evaluation of Infinitopes’ AI/ML-precision targeted, off-the-shelf vaccine platform to prevent recurrence after surgical resection. We aim to lead the development of innovative medicines that bring hope to patients suffering from cancers with unmet medical needs. Thank you to the Taylor Wessing team for their outstanding support throughout the process. The team's expertise and thorough understanding of both our business and the complex demands of life sciences financing have been instrumental in enabling us to reach this important milestone."
Our team consisted of Ross McNaughton (Partner) and Oli Denne (Senior Associate) in the Corporate team.
